

Renata Čáfková

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8505164/publications.pdf>

Version: 2024-02-01

247
papers

91,666
citations

9428

76
h-index

1333

229
g-index

264
all docs

264
docs citations

264
times ranked

84190
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 5-115.	0.8	220
2	Gender differences in secondary prevention of coronary heart disease: Far from closing the gap. <i>International Journal of Cardiology</i> , 2022, 355, 52-53.	0.8	0
3	Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?. <i>Atherosclerosis</i> , 2022, 348, 25-35.	0.4	18
4	Mild chronic hypertension in pregnancy: to treat or wait?. <i>Blood Pressure</i> , 2022, 31, 121-124.	0.7	1
5	High leptin status indicates an increased risk of mortality and heart failure in stable coronary artery disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 2137-2146.	1.1	1
6	Serum Bilirubin Concentrations and the Prevalence of Gilbert Syndrome in Elite Athletes. <i>Sports Medicine - Open</i> , 2022, 8, .	1.3	9
7	Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 370-379.	0.8	83
8	The role of advanced glycation end products in vascular aging: which parameter is the most suitable as a biomarker?. <i>Journal of Human Hypertension</i> , 2021, 35, 240-249.	1.0	14
9	The Prognostic Importance of Impaired Fasting Glycemia in Chronic Coronary Heart Disease Patients. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, 29-35.	0.6	3
10	The coincidence of low vitamin K status and high expression of growth differentiation factor 15 may indicate increased mortality risk in stable coronary heart disease patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 540-551.	1.1	6
11	Reference values of retinal microcirculation parameters derived from a population random sample. <i>Microvascular Research</i> , 2021, 134, 104117.	1.1	5
12	Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. <i>European Heart Journal</i> , 2021, 42, 967-984.	1.0	136
13	Serum biomarkers, skin autofluorescence and other methods. Which parameter better illustrates the relationship between advanced glycation end products and arterial stiffness in the general population?. <i>Hypertension Research</i> , 2021, 44, 518-527.	1.5	14
14	Hypertrophic remodelling of retinal arterioles in patients with congestive heart failure. <i>ESC Heart Failure</i> , 2021, 8, 1892-1900.	1.4	1
15	Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight. <i>ELife</i> , 2021, 10, .	2.8	41
16	Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control. <i>Diabetologia</i> , 2021, 64, 2012-2025.	2.9	24
17	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	1.0	2,517
18	Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. <i>Lancet, The</i> , 2021, 398, 957-980.	6.3	1,289

#	ARTICLE	IF	CITATIONS
19	Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients. <i>Biomarkers in Medicine</i> , 2021, 15, 1465-1477.	0.6	1
20	The prognostic importance of subclinical heart failure in stable coronary heart disease patients. <i>Acta Cardiologica</i> , 2020, 75, 329-336.	0.3	4
21	Mood disorders impaired quality of life but not the mortality or morbidity risk in stable coronary heart disease patients. <i>Acta Cardiologica</i> , 2020, 75, 667-675.	0.3	8
22	Soluble receptor for advanced glycation end-products independently influences individual age-dependent increase of arterial stiffness. <i>Hypertension Research</i> , 2020, 43, 111-120.	1.5	9
23	Comparison of three office blood pressure measurement techniques and their effect on hypertension prevalence in the general population. <i>Journal of Hypertension</i> , 2020, 38, 656-662.	0.3	15
24	Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 384-393.	1.4	24
25	Is There Really an Association of High Circulating Adiponectin Concentration and Mortality or Morbidity Risk in Stable Coronary Artery Disease?. <i>Hormone and Metabolic Research</i> , 2020, 52, 861-868.	0.7	2
26	Which serum uric acid levels are associated with increased cardiovascular risk in the general adult population?. <i>Journal of Clinical Hypertension</i> , 2020, 22, 897-905.	1.0	4
27	Longitudinal trends in the prevalence of hyperuricaemia and chronic kidney disease in hypertensive and normotensive adults. <i>Blood Pressure</i> , 2020, 29, 308-318.	0.7	5
28	30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post-MONICA, 1985–2016/17. <i>PLoS ONE</i> , 2020, 15, e0232845.	1.1	34
29	Systematic COronary Risk Evaluation (SCORE) and 20-year risk of cardiovascular mortality and cancer. <i>European Journal of Internal Medicine</i> , 2020, 79, 63-69.	1.0	3
30	Hypertension and Reproduction. <i>Current Hypertension Reports</i> , 2020, 22, 29.	1.5	14
31	Synergistic effect of sclerostin and angiotensin II receptor 1 polymorphism on arterial stiffening. <i>Biomarkers in Medicine</i> , 2020, 14, 173-184.	0.6	1
32	Primary aldosteronism in a general population sample. The Czech post-MONICA study. <i>Blood Pressure</i> , 2020, 29, 191-198.	0.7	4
33	Serum Bilirubin in the Czech Population—Relationship to the Risk of Myocardial Infarction in Males. <i>Circulation Journal</i> , 2020, 84, 1779-1785.	0.7	8
34	(The prevalence of major cardiovascular risk factors in the Czech population in 2015-2018. The Czech) <i>TJ ETQq0 0 0 rgBT /Overlock 10 T</i>	0.7	8
35	Adherence to cardiovascular prevention principles in subjects at high risk. <i>Vnitřní Lekarství</i> , 2020, 66, e5-e12.	0.1	0
36	Title is missing!. , 2020, 15, e0232845.		0

#	ARTICLE	IF	CITATIONS
37	Title is missing!. , 2020, 15, e0232845.		0
38	Title is missing!. , 2020, 15, e0232845.		0
39	Title is missing!. , 2020, 15, e0232845.		1
40	Normative reference ranges for echocardiographic chamber dimensions in a healthy Central European population: results from the Czech post-MONICA survey. <i>Cardiovascular Ultrasound</i> , 2019, 17, 22.	0.5	3
41	Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. <i>Nature Genetics</i> , 2019, 51, 1459-1474.	9.4	251
42	A catalog of genetic loci associated with kidney function from analyses of a million individuals. <i>Nature Genetics</i> , 2019, 51, 957-972.	9.4	549
43	The low expression of circulating microRNA-19a represents an additional mortality risk in stable patients with vascular disease. <i>International Journal of Cardiology</i> , 2019, 289, 101-106.	0.8	26
44	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 824-835.	0.8	558
45	Blood pressure distribution and control in coronary patients from 24 European countries in the European Society of Cardiology EURoObservational Research Programme European survey of cardiovascular disease prevention and diabetes. EUROASPIRE IV Registry. <i>Journal of Hypertension</i> , 2019, 37, 2015-2023.	0.3	7
46	Uromodulin in a Pathway Between Decreased Renal Urate Excretion and Albuminuria. <i>American Journal of Hypertension</i> , 2019, 32, 384-392.	1.0	4
47	Arterial Hypertension and Cardiovascular Risk. , 2019, , 57-74.		0
48	Is the impact of conventional risk factors the same in men and women? Plea for a more gender-specific approach. <i>International Journal of Cardiology</i> , 2019, 286, 214-219.	0.8	30
49	Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. <i>European Journal of Epidemiology</i> , 2019, 34, 247-258.	2.5	22
50	Alcohol and cardiovascular disease: Position Paper of the Czech Society of Cardiology. <i>Central European Journal of Public Health</i> , 2019, 27, S6-S9.	0.4	5
51	The changes in achievement of target LDL-cholesterol levels between 2006 and 2017 in Czech patients with chronic coronary heart disease. <i>Cor Et Vasa</i> , 2019, 61, 20-27.	0.1	1
52	Current status of secondary prevention in Czech coronary patients in the EUROASPIRE V Study. <i>Cor Et Vasa</i> , 2019, 61, e277-e283.	0.1	0
53	Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants. <i>International Journal of Epidemiology</i> , 2018, 47, 872-883i.	0.9	65
54	Hypertension. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18014.	18.1	636

#	ARTICLE	IF	CITATIONS
55	Left ventricular hypertrophy in females with hypertension is associated with a poor prognosis. <i>International Journal of Cardiology</i> , 2018, 258, 277-278.	0.8	1
56	Serum Vitamin D Status, Vitamin D Receptor Polymorphism, and Glucose Homeostasis in Healthy Subjects. <i>Hormone and Metabolic Research</i> , 2018, 50, 56-64.	0.7	9
57	Should 24-Hour Ambulatory Blood Pressure Monitoring Become Part of Regular Checkup in Women With Previous Preeclampsia?. <i>Hypertension</i> , 2018, 71, 59-60.	1.3	4
58	Prospective study of metabolic syndrome as a mortality marker in chronic coronary heart disease patients. <i>European Journal of Internal Medicine</i> , 2018, 47, 55-61.	1.0	10
59	Kardiovize Brno 2030, a prospective cardiovascular health study in Central Europe: Methods, baseline findings and future directions. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 54-64.	0.8	45
60	Cardiovascular Sequels of Hypertension in Pregnancy. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	8
61	Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. <i>International Journal of Cardiology</i> , 2018, 272, 20-25.	0.8	24
62	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 3021-3104.	1.0	6,826
63	2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>European Heart Journal</i> , 2018, 39, 3165-3241.	1.0	1,396
64	Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 196-213.	5.5	90
65	The risk profile of patients with acute coronary syndrome treated at IKEM between 2006 and 2013. <i>Cor Et Vasa</i> , 2017, 59, e119-e127.	0.1	5
66	Synergistic effect of low K and D vitamin status on arterial stiffness in a general population. <i>Journal of Nutritional Biochemistry</i> , 2017, 46, 83-89.	1.9	16
67	The polypill in cardiovascular prevention. <i>Journal of Hypertension</i> , 2017, 35, 1546-1553.	0.3	48
68	Reference values of cardio-ankle vascular index in a random sample of a white population. <i>Journal of Hypertension</i> , 2017, 35, 2238-2244.	0.3	23
69	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1713-1722.	13.9	4,179
70	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	13.9	510
71	Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. <i>Lancet</i> , 2017, 390, 2627-2642.	6.3	5,010
72	Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. <i>Lancet</i> , 2017, 389, 37-55.	6.3	1,667

#	ARTICLE	IF	CITATIONS
73	Reply. <i>Journal of Hypertension</i> , 2017, 35, 2551-2552.	0.3	0
74	Response to Letter to the Editor entitled Oxidative Stress Participates in the Associations Between Serum Uric Acid and Albuminuria in Obesity. <i>American Journal of Hypertension</i> , 2017, 30, e2-e3.	1.0	1
75	Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999-2013. <i>Global Heart</i> , 2017, 12, 315.	0.9	81
76	Current trends in drug treatment of hypertension. <i>Interni Medicina Pro Praxi</i> , 2017, 19, 10-15.	0.0	1
77	Current and past smoking patterns in a Central European urban population: a cross-sectional study in a high-burden country. <i>BMC Public Health</i> , 2016, 16, 571.	1.2	15
78	Changes in Hypertension Prevalence, Awareness, Treatment, and Control in High-, Middle-, and Low-Income Countries: An Update. <i>Current Hypertension Reports</i> , 2016, 18, 62.	1.5	33
79	Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT. <i>Journal of Hypertension</i> , 2016, 34, 393-396.	0.3	26
80	Threshold for diagnosing hypertension by automated office blood pressure using random sample population data. <i>Journal of Hypertension</i> , 2016, 34, 2180-2186.	0.3	43
81	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2009-2020.	13.9	526
82	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2021-2031.	13.9	641
83	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2032-2043.	13.9	299
84	A comparison of secondary prevention practice in poststroke and coronary heart disease patients. <i>Public Health</i> , 2016, 137, 64-72.	1.4	5
85	Exploring potential mortality reductions in 9 European countries by improving diet and lifestyle: A modelling approach. <i>International Journal of Cardiology</i> , 2016, 207, 286-291.	0.8	19
86	The abnormal status of uncarboxylated matrix Gla protein species represents an additional mortality risk in heart failure patients with vascular disease. <i>International Journal of Cardiology</i> , 2016, 203, 916-922.	0.8	24
87	Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. <i>Lancet</i> , 2016, 387, 1513-1530.	6.3	2,842
88	Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 2 million participants. <i>Lancet</i> , 2016, 387, 1377-1396.	6.3	3,941
89	The Impact of Blood Pressure and Visceral Adiposity on the Association of Serum Uric Acid With Albuminuria in Adults Without Full Metabolic Syndrome. <i>American Journal of Hypertension</i> , 2016, 29, 1335-1342.	1.0	14
90	The changes of secondary prevention practice in Czech post-stroke patients between 2007 and 2012/13. <i>Cor Et Vasa</i> , 2016, 58, e367-e373.	0.1	1

#	ARTICLE	IF	CITATIONS
91	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 636-648.	0.8	772
92	Desphospho-uncarboxylated matrix Gla protein is associated with increased aortic stiffness in a general population. <i>Journal of Human Hypertension</i> , 2016, 30, 418-423.	1.0	55
93	ESHRE Guideline: management of women with premature ovarian insufficiency. <i>Human Reproduction</i> , 2016, 31, 926-937.	0.4	916
94	Soluble receptor for advanced glycation end products and increased aortic stiffness in the general population. <i>Hypertension Research</i> , 2016, 39, 266-271.	1.5	22
95	Educational level and risk profile and risk control in patients with coronary heart disease. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 881-890.	0.8	33
96	Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0147601.	1.1	882
97	Epidemiology of Hypertension and Brain Disease. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2016, , 1-11.	0.1	0
98	Low blood pressure during the acute period of ischemic stroke is associated with decreased survival. <i>Journal of Hypertension</i> , 2015, 33, 339-345.	0.3	50
99	Blood pressure control and risk profile in poststroke survivors. <i>Journal of Hypertension</i> , 2015, 33, 2107-2114.	0.3	9
100	Dyslipidemia and Cardiovascular Disease in Women. <i>Current Cardiology Reports</i> , 2015, 17, 609.	1.3	62
101	Differential effect of metabolic syndrome on various parameters of arterial stiffness. <i>Blood Pressure</i> , 2015, 24, 206-211.	0.7	5
102	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. <i>Cardiovascular Diabetology</i> , 2015, 14, 133.	2.7	101
103	The Obesity Paradox and Survivors of Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 1443-1450.	0.7	42
104	Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV – a survey from the European Society of Cardiology. <i>European Heart Journal</i> , 2015, 36, 1171-1177.	1.0	81
105	Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331 288 participants. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 624-637.	5.5	139
106	Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1354-1362.	0.8	81
107	A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 339-355.	5.5	185
108	Tobacco smoking strongly modifies the association of prothrombin G20210A with undetermined stroke: Consecutive survivors and population-based controls. <i>Atherosclerosis</i> , 2015, 240, 446-452.	0.4	9

#	ARTICLE	IF	CITATIONS
109	The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation. <i>Atherosclerosis</i> , 2015, 241, 507-532.	0.4	587
110	Quality of Life Predictors in Chronic Stable Post-Stroke Patients and Prognostic Value of SF-36 Score as a Mortality Surrogate. <i>Translational Stroke Research</i> , 2015, 6, 375-383.	2.3	26
111	Adverse Lifestyle Trends Counter Improvements in Cardiovascular Risk Factor Management in Coronary Patients. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1634-1636.	1.2	11
112	The DRD2/ANKK1 Taq1A polymorphism is associated with smoking cessation failure in patients with coronary heart disease. <i>Personalized Medicine</i> , 2015, 12, 463-473.	0.8	4
113	The association between uncarboxylated matrix Gla protein and lipoprotein-associated phospholipase A2. <i>Maturitas</i> , 2015, 80, 82-88.	1.0	4
114	The predictive potential of asymptomatic mild elevation of cardiac troponin I on mortality risk of stable patients with vascular disease. <i>Clinical Biochemistry</i> , 2015, 48, 353-357.	0.8	1
115	Positive effects of antihypertensive treatment on aortic stiffness in the general population. <i>Hypertension Research</i> , 2014, 37, 64-68.	1.5	17
116	Comparison of Noninvasive Assessments of Central Blood Pressure Using General Transfer Function and Late Systolic Shoulder of the Radial Pressure Wave. <i>American Journal of Hypertension</i> , 2014, 27, 162-168.	1.0	12
117	Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 829-839.	0.8	52
118	2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. <i>Blood Pressure</i> , 2014, 23, 3-16.	0.7	565
119	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline. <i>Journal of Hypertension</i> , 2014, 32, 1741-1750.	0.3	39
120	Why COLM and ACCOMPLISH study results differ. <i>Journal of Hypertension</i> , 2014, 32, 1967-1969.	0.3	0
121	Summary of the European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): Prepared by the Czech Society of Cardiology. <i>Cor Et Vasa</i> , 2014, 56, e169-e189.	0.1	7
122	Tobacco use and some characteristics of tobacco users. Preliminary results of "Kardiovizie Brno 2030". <i>Cor Et Vasa</i> , 2014, 56, e118-e127.	0.1	4
123	Availability and use of home blood pressure measurement in the Czech general population. <i>Cor Et Vasa</i> , 2014, 56, e158-e163.	0.1	6
124	Residual cardiovascular risk in patients with stable coronary heart disease over the last 16 years (Czech part of the EUROASPIRE I-IV surveys). <i>Cor Et Vasa</i> , 2014, 56, e98-e104.	0.1	6
125	State of secondary prevention in Czech coronary patients in the EUROASPIRE IV study. <i>Cor Et Vasa</i> , 2014, 56, e105-e112.	0.1	3
126	Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 634-647.	5.5	591

#	ARTICLE	IF	CITATIONS
127	Desphospho-uncarboxylated matrix Gla-protein is associated with mortality risk in patients with chronic stable vascular disease. <i>Atherosclerosis</i> , 2014, 235, 162-168.	0.4	75
128	Relationship between measures of central and general adiposity with aortic stiffness in the general population. <i>Atherosclerosis</i> , 2014, 235, 625-631.	0.4	48
129	Large artery stiffness and carotid flow pulsatility in stroke survivors. <i>Journal of Hypertension</i> , 2014, 32, 1097-1103.	0.3	26
130	Hypertriglyceridemic waist increased risk of inappropriate glucose control in patients with coronary heart disease. <i>Clinical Lipidology</i> , 2014, 9, 515-522.	0.4	2
131	Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient. <i>Journal of Hypertension</i> , 2014, 32, 1888-1897.	0.3	65
132	Antiplatelet and Lipid-lowering Drugs in Hypertension. <i>European Cardiology Review</i> , 2014, 9, 16.	0.7	2
133	Lower-extremity arterial stiffness vs. aortic stiffness in the general population. <i>Hypertension Research</i> , 2013, 36, 718-724.	1.5	38
134	Arterial stiffness parameters: How do they differ?. <i>Atherosclerosis</i> , 2013, 231, 359-364.	0.4	33
135	Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. <i>European Heart Journal</i> , 2013, 34, 2149-2157.	1.0	225
136	Association between endothelial NO synthase polymorphism (rs3918226) and arterial properties. <i>Artery Research</i> , 2013, 7, 54.	0.3	2
137	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). <i>Revista Española De Cardiología</i> , 2013, 66, 880.e1-880.e64.	0.6	24
138	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>Blood Pressure</i> , 2013, 22, 193-278.	0.7	355
139	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2013, 34, 2159-2219.	1.0	5,681
140	The Global Cardiovascular Risk Transition. <i>Circulation</i> , 2013, 127, 1493-1502.	1.6	205
141	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>Journal of Hypertension</i> , 2013, 31, 1281-1357.	0.3	4,251
142	Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe. <i>Journal of Hypertension</i> , 2013, 31, 2018-2024.	0.3	58
143	Is Diabetes Mellitus a Heart Disease Equivalent in Women?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 164-170.	0.9	18
144	2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). <i>Journal of Hypertension</i> , 2013, 31, 1925-1938.	0.3	789

#	ARTICLE	IF	CITATIONS
145	Exercise testing in hypertensive patients for assessing the cardiovascular protective potential of antihypertensive drugs. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2013, 7, 99-108.	1.0	2
146	Guidelines and research upon which guidelines are founded. <i>Journal of Hypertension</i> , 2013, 31, 1279-1280.	0.3	0
147	Wytyczne ESH/ESC dotyczÄ...ce postÄ™powania w nadciÄnieniu tÄ™tnicznym w 2013 roku. <i>Kardiologia Polska</i> , 2013, 71, 27-118.	0.3	4
148	Resistant Hypertension: Definition, Prevalence, and Cardiovascular Risk. , 2013, , 1-8.		0
149	The association between low 25-hydroxyvitamin D and increased aortic stiffness. <i>Journal of Human Hypertension</i> , 2012, 26, 650-655.	1.0	39
150	Relation of central and brachial blood pressure to left ventricular hypertrophy. The Czech Post-MONICA Study. <i>Journal of Human Hypertension</i> , 2012, 26, 14-19.	1.0	31
151	Hypertension and atrial fibrillation. <i>Journal of Hypertension</i> , 2012, 30, 239-252.	0.3	177
152	Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2012, 367, 2204-2213.	13.9	1,145
153	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). <i>Atherosclerosis</i> , 2012, 223, 1-68.	0.4	414
154	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). <i>European Heart Journal</i> , 2012, 33, 1635-1701.	1.0	5,247
155	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq1 1 0.784314 rgBT /Overl Prevention & Rehabilitation (EACPR). [Eur Heart J 2012;33:1635-1701. doi: 10.1093/eurheartj/ehs092]. European Heart Journal , 2012, 33, 2126-2126.	1.0	79
156	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). <i>European Journal of Preventive Cardiology</i> , 2012, 19, 585-667.	0.8	359
157	GuÃa de prÃctica clÃnica de la ESC para el tratamiento de las enfermedades cardiovasculares durante el embarazo. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 171.e1-171.e44.	0.6	12
158	Risk stratification in cardiovascular disease primary prevention â€“ scoring systems, novel markers, and imaging techniques. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 163-174.	1.0	32
159	National, regional, and global trends in adult overweight and obesity prevalences. <i>Population Health Metrics</i> , 2012, 10, 22.	1.3	730
160	European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). <i>International Journal of Behavioral Medicine</i> , 2012, 19, 403-488.	0.8	224
161	Assessment of Total Cardiovascular Risk in Hypertension: The Role of Subclinical Organ Damage. , 2012, , 199-211.		0
162	Carotid intima-media thickness in young survivors of acute myocardial infarction. <i>Experimental and Clinical Cardiology</i> , 2012, 17, 215-20.	1.3	2

#	ARTICLE	IF	CITATIONS
163	Why is the treatment of hypertension in pregnancy still so difficult?. Expert Review of Cardiovascular Therapy, 2011, 9, 647-649.	0.6	10
164	Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. New England Journal of Medicine, 2011, 364, 907-917.	13.9	741
165	Plasma HDL-cholesterol and triglyceride levels in familial hypercholesterolemia: Data from the MedPed CZ database and the Czech population. Clinica Chimica Acta, 2011, 412, 920-924.	0.5	4
166	ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 3147-3197.	1.0	1,694
167	National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet, The, 2011, 377, 568-577.	6.3	884
168	National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet, The, 2011, 377, 557-567.	6.3	3,476
169	National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet, The, 2011, 377, 578-586.	6.3	445
170	National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet, The, 2011, 378, 31-40.	6.3	3,019
171	Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. European Heart Journal, 2011, 32, 218-225.	1.0	70
172	Blood Pressure-Lowering Aspects of Lipid-Lowering and Anti-Diabetic Drugs. Pharmaceuticals, 2011, 4, 1-6.	1.7	2
173	Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. European Heart Journal, 2011, 32, 1424-1431.	1.0	175
174	Can blood pressure in the first trimester predict the development of gestational hypertensive disorders?. European Heart Journal, 2011, 32, 3067-3069.	1.0	1
175	A high ankle-brachial index is associated with increased aortic pulse wave velocity: the Czech post-MONICA study. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 790-796.	3.1	15
176	The prevalence of major cardiovascular risk factors in the Czech population in 2006-2009. The Czech post-MONICA study. Cor Et Vasa, 2011, 53, 220-229.	0.1	27
177	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. European Journal of Anaesthesiology, 2010, 27, 92-137.	0.7	263
178	Agreement within Europe about antihypertensive treatment and education – results from the European Society of Hypertension questionnaire. Journal of Hypertension, 2010, 28, 1593-1594.	0.3	2
179	An inverse association between serum leptin concentration and reported alcohol intake in patients with manifest vascular disease. European Journal of Clinical Nutrition, 2010, 64, 1350-1357.	1.3	2
180	Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. Journal of Hypertension, 2010, 28, 2196-2203.	0.3	72

#	ARTICLE	IF	CITATIONS
181	Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. <i>New England Journal of Medicine</i> , 2010, 363, 905-917.	13.9	791
182	Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. <i>Czech MONICA and Czech post-MONICA. Atherosclerosis</i> , 2010, 211, 676-681.	0.4	134
183	Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. <i>Annals of Medicine</i> , 2010, 42, 447-464.	1.5	49
184	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Journal of Hypertension</i> , 2009, 27, 2121-2158.	0.3	1,236
185	Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. <i>Neurology</i> , 2009, 72, 688-694.	1.5	86
186	N-terminal pro B-type natriuretic peptide as prognostic marker for mortality in coronary patients without clinically manifest heart failure. <i>European Journal of Epidemiology</i> , 2009, 24, 363-368.	2.5	18
187	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Blood Pressure</i> , 2009, 18, 308-347.	0.7	351
188	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. <i>European Heart Journal</i> , 2009, 30, 2769-2812.	1.0	735
189	Hypovolaemia-induced metabolic dysfunction, mediated in part by aldosterone and angiotensin. <i>Journal of Hypertension</i> , 2009, 27, 2116-2117.	0.3	0
190	Statins and hypertension. <i>Journal of Hypertension</i> , 2009, 27, 662-665.	0.3	4
191	Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2009, 27, 1719-1742.	0.3	620
192	Mechanisms of hypertension in the cardiometabolic syndrome. <i>Journal of Hypertension</i> , 2009, 27, 441-451.	0.3	63
193	Hypertension in the metabolic syndrome: summary of the new position statement of the European Society of Hypertension. <i>Polish Archives of Internal Medicine</i> , 2009, 119, 255-260.	0.3	2
194	Prevalence and Risk of Hypertension in Renal Disease – Data from the Czech Registry of Renal Biopsies. <i>Kidney and Blood Pressure Research</i> , 2008, 31, 135-142.	0.9	5
195	Synergistic effect of angiotensin II type 1 receptor and endothelial nitric oxide synthase gene polymorphisms on arterial stiffness. <i>Journal of Human Hypertension</i> , 2008, 22, 111-118.	1.0	12
196	Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women. <i>Stroke</i> , 2008, 39, 2444-2448.	1.0	76
197	European guidelines on cardiovascular disease prevention in clinical practice: past, present, and future: a need for joint forces. <i>Journal of Hypertension</i> , 2008, 26, 157-160.	0.3	4
198	The metabolic syndrome in hypertension: European society of hypertension position statement. <i>Journal of Hypertension</i> , 2008, 26, 1891-1900.	0.3	107

#	ARTICLE	IF	CITATIONS
199	Blood pressure around the menopause: a population study. Journal of Hypertension, 2008, 26, 1976-1982.	0.3	68
200	The quality of secondary prevention of coronary heart disease in Czech patients in the EURO-ASPIRE III survey.. Cor Et Vasa, 2008, 50, 156-162.	0.1	13
201	The standard of secondary prevention of stroke in Czech patients in the EUROASPIRE III Study - Stroke Specific Module. Cor Et Vasa, 2008, 50, 446-454.	0.1	10
202	Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq0 0 0.1gBT /Overlock 10 T	0.1	10
203	2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1105-1187.	0.3	4,778
204	2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1751-1762.	0.3	1,152
205	European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis, 2007, 194, 1-45.	0.4	292
206	WO16-OR-5 RECENT CHANGES OF RISK FACTORS OF CHD IN THE CZECH POPULATION. Atherosclerosis Supplements, 2007, 8, 17.	1.2	0
207	2007 ESH&ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2007, 16, 135-232.	0.7	292
208	Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq0 0 0.1gBT /Overlock 10 T	0.1	10
209	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq1 1 0.784314 2,331gBT /Over	1.0	2,331
210	The metabolic syndrome in hypertension: Diagnostic and therapeutic implications. Current Hypertension Reports, 2007, 9, 305-313.	1.5	8
211	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 2006, 28, 1462-1536.	1.0	1,617
212	Highlights from International Congress. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 61-72.	1.0	0
213	European Society of Hypertension Scientific Newsletter: Update on Hypertension Management: Prevention of type 2 diabetes mellitus with antihypertensive drugs. Journal of Hypertension, 2006, 24, 2478-2482.	0.3	6
214	ESH statement on detection and punishment of abstract fraud and poster plagiarism. Journal of Hypertension, 2006, 24, 203-204.	0.3	1
215	Update on Hypertension Management: Treatment of hypertension in patients with type 2 diabetes mellitus. Journal of Hypertension, 2006, 24, 208-210.	0.3	8
216	Mild hyperhomocysteinaemia is associated with increased aortic stiffness in general population. Journal of Human Hypertension, 2006, 20, 267-271.	1.0	33

#	ARTICLE	IF	CITATIONS
217	ESH-ESC Guidelines for the Management of Hypertension. Herz, 2006, 31, 331-338.	0.4	52
218	Treatment of hypertension in patients with type-2 diabetes mellitus. Blood Pressure, 2006, 15, 62-63.	0.7	0
219	The burden of hypertension and inadequate control in populations. Journal of Hypertension, 2006, 24, 807-809.	0.3	6
220	Large artery stiffness and pulse wave reflection: Results of a population-based study. Blood Pressure, 2005, 14, 45-52.	0.7	45
221	ESH statement on detection and punishment of abstract fraud and poster plagiarism. Blood Pressure, 2005, 14, 322-323.	0.7	1
222	W11-P-004 The metabolic syndrome in a Czech population random sample: A Czech post-Monica study. Atherosclerosis Supplements, 2005, 6, 57.	1.2	0
223	W16-IS-001 Assessment of global cardiovascular risk. Atherosclerosis Supplements, 2005, 6, 98.	1.2	0
224	T01-P-005 Hyperuricemia – The forgotten component of metabolic syndrome?. Atherosclerosis Supplements, 2005, 6, 134.	1.2	0
225	T01-P-006 Prediction of diabetes in individuals with impaired fasting glucose in the Czech population in the 1997/98 to 2000/01 period. Atherosclerosis Supplements, 2005, 6, 134.	1.2	1
226	Introduction. Blood Pressure, 2005, 14, 2-2.	0.7	0
227	Arterial hypertension as a public health issue in the Czech Republic. Blood Pressure, 2005, 14, 25-28.	0.7	38
228	The scope of hypertension. Blood Pressure, 2005, 14, 3-5.	0.7	1
229	The Renin-Angiotensin System, Capri 2005. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 91-108.	1.0	0
230	Prevalence, awareness, treatment, and control of hypertension in the Czech Republic. Results of two nationwide cross-sectional surveys in 1997/1998 and 2000/2001, Czech Post-MONICA Study. Journal of Human Hypertension, 2004, 18, 571-579.	1.0	45
231	European guidelines on cardiovascular disease prevention in clinical practice <SBT>Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis, 2004, 173, 379-389.	0.4	184
232	Trends in blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2000/01. Journal of Hypertension, 2004, 22, 1479-1485.	0.3	51
233	Resumen Ejecutivo: Guía Europea de Prevención Cardiovascular en la práctica clínica. Revista Española De Salud Pública, 2004, 78, 439-456.	0.3	6
234	European guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis, 2003, 171, 145-155.	0.4	106

#	ARTICLE	IF	CITATIONS
235	European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <i>European Heart Journal</i> , 2003, 24, 1601-1610.	1.0	1,588
236	Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. <i>Human Reproduction</i> , 2003, 18, 980-984.	0.4	59
237	European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, S1-S10.	3.1	205
238	European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, S1-S78.	3.1	174
239	European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, S1-S10.	3.1	152
240	Blood pressure, endothelial function and circulating endothelin concentrations in liver transplant recipients. <i>Journal of Hypertension</i> , 2001, 19, 1359-1367.	0.3	11
241	Cyclosporin-induced hypertension. <i>Journal of Hypertension</i> , 2001, 19, 2283-2285.	0.3	18
242	Hypertension in pregnancy. <i>Journal of Hypertension</i> , 2000, 18, 1346-1348.	0.3	2
243	Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. <i>Journal of Human Hypertension</i> , 2000, 14, 347-354.	1.0	14
244	Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. <i>Human Reproduction</i> , 2000, 15, 785-789.	0.4	223
245	Triglycerides, remnant lipoprotein particles and preclinical atherosclerosis in the Czech population. <i>Atherosclerosis</i> , 1999, 144, 126-127.	0.4	2
246	Valsartan and atenolol in patients with severe essential hypertension. <i>Journal of Human Hypertension</i> , 1998, 12, 563-567.	1.0	30
247	A Comparison of the Effects of Mibefradil and Atenolol on Regression of Left Ventricular Hypertrophy in Hypertensive Patients. <i>Cardiology</i> , 1998, 89, 263-270.	0.6	15